Send to

Choose Destination
Mol Cancer Ther. 2018 May;17(5):1024-1038. doi: 10.1158/1535-7163.MCT-17-0200. Epub 2018 Mar 15.

Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein.

Author information

Department of Oncology Research, MedImmune, Gaithersburg, Maryland.
Department of Antibody Development and Protein Engineering, MedImmune, Gaithersburg, Maryland.
Translational Science, MedImmune, Gaithersburg, Maryland.
Department of Toxicology, MedImmune, Gaithersburg, Maryland.
Innovative Medicines, Oncology, AstraZeneca, Cambridge, United Kingdom.
Vaccine and Gene Therapy Institute, Departments of Molecular Microbiology and Pathology, and the Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon.
Earle A. Chiles Research Institute, Providence Cancer Center, Portland, Oregon.
AgonOx, Portland, Oregon.
Department of Oncology Research, MedImmune, Gaithersburg, Maryland.


Ligation of OX40 (CD134, TNFRSF4) on activated T cells by its natural ligand (OX40L, CD252, TNFSF4) enhances cellular survival, proliferation, and effector functions such as cytokine release and cellular cytotoxicity. We engineered a recombinant human OX40L IgG4P Fc fusion protein termed MEDI6383 that assembles into a hexameric structure and exerts potent agonist activity following engagement of OX40. MEDI6383 displayed solution-phase agonist activity that was enhanced when the fusion protein was clustered by Fc gamma receptors (FcγRs) on the surface of adjacent cells. The resulting costimulation of OX40 on T cells induced NFκB promoter activity in OX40-expressing T cells and induced Th1-type cytokine production, proliferation, and resistance to regulatory T cell (Treg)-mediated suppression. MEDI6383 enhanced the cytolytic activity of tumor-reactive T cells and reduced tumor growth in the context of an alloreactive human T cell:tumor cell admix model in immunocompromised mice. Consistent with the role of OX40 costimulation in the expansion of memory T cells, MEDI6383 administered to healthy nonhuman primates elicited peripheral blood CD4 and CD8 central and effector memory T-cell proliferation as well as B-cell proliferation. Together, these results suggest that OX40 agonism has the potential to enhance antitumor immunity in human malignancies. Mol Cancer Ther; 17(5); 1024-38. ©2018 AACR.

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center